Podcast CME Course Information
Exam: Exam 436: Determining clinically meaningful decline in preclinical Alzheimer disease
Issue: July 23, 2019
Determining clinically meaningful decline in preclinical Alzheimer disease
Upon completion of this podcast, listeners will learn that a preclinical Alzheimer disease (AD) population declines to the cognitive performance of an early MCI population in 6 years. Designers of preclinical AD treatment trials need to prepare for larger and longer trials than are currently being considered. Interactions with Aβ status were inconsistent and not readily generalizable.
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.
- Patient Care
- Medical Knowledge
Program Accreditations Subcommittee (PAS) is responsible for reviewing and evaluating all CME programs. Joseph F. Kass, MD, JD, FAAN, has received personal compensation for activities as an expert witness in litigation and in an editorial capacity for the American Academy of Neurology. Barney J. Stern, MD, FAAN, has received personal compensation for book chapter contributions. The other members of the committee (Samir Belagaje, MD; J. Clay Goodman, MD, FAAN; Omotola A. Hope, MD; Shannon M. Kilgore, MD, FAAN) and AAN staff (Kristine Mitchell) report no disclosures. Robert A. Gross, MD, PhD, FAAN, has received funding for travel and/or speaker honoraria from the American Academy of Neurology; receives a stipend as Editor-in-Chief of Neurology; has received consultant fees from GlaxoSmithKline and Harris Interactive; has served on speakers' bureaus for Abbott, UCB, and GlaxoSmithKline; has conducted clinical trials over the past 5 years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus, but has ceased participation in industry-sponsored clinical trials and speakers' bureaus since his appointment as Neurology EIC in 2010; and has received research support from the Department of the Army, UCBPharma, and University of Rochester Medical Center/NIH. Dr. Stacey Clardy serves as Podcast Editor for Neurology® and has received research support forWestern Institute for Biomedical Research (WIBR). Dr. Jeff Ratliff serves as Podcast Deputy Editor for Neurology andreceived a speaker honorarium from Haverford College. AAN staff members editing the test (P Baskin, L Kleffman, K Aman Ramm) have no disclosures. The CME Journal Editors who have reviewed the exam are James WM Owens Jr., MD PhD, who receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology and Adam Kelly, MD, who has served as Guest Editor of Continuum (April 2014) and receives a stipend in his editorial capacity for Neurology.
Disclosures: Dr. Gregory Day has served on the editorial boards for DynaMed and EBSCO; has received commercial research support from Avid Pharmaceuticals, Eli Lilly, Roche, and Biogen; has received academic research support from the Barnes Jewish Hospital Foundation and the Chan Zuckerberg Foundation; has received foundation/society research support from the American Brain Foundation and Eugene M Johnson Jr. Weston Brain Institute; holds stock options in ANI Pharmaceuticals; and has acted as a consultant in legal proceedings for Hendrick Medical Center. Dr. Jeffrey Ratliff has received speaker or travel honoraria from Teva and US WorldMeds LLC; serves as the Deputy Section Editor for Neurology Podcast; has served as a consultant for UCB Pharmaceuticals, US World Meds, LLC, Medscape, and Retrophin, Inc.; and has served on speaker’s bureaus for Teva and US WorldMeds LLC. Dr. Sarah Tabrizi has served on the scientific advisory boards, through the offices of UCL Consultants, Ltd., through University College London, of F. Hoffmann-La Roche Ltd., Takeda Pharmaceuticals Ltd., and Triplet Therapeutics; has served as a consultant, for UCL Consultants, Ltd., through University College London, for Alnylam Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Genentech, GSK, Heptares Therapeutics, Takeda Pharmaceuticals Ltd, Teva Pharmaceuticals, Triplet Theraputics, UCB Pharma S.A., University College Irvine, and Vertex Pharmaceuticals Incorporated and has served as a direct consultant for Alphasights, Decision Resources Group, and Triangle Insights Group; has received commercial research support from Takeda Pharmaceuticals and Cantervale Limited; has received governmental research support from Medical Research Council UK; has received academic research support NIHR North Thames Local Clinical Research Network and UK Dementia Research Institute; and has received foundation/society research support from Wellcome Trust, CHDI Foundation, Wolfson Foundation, and Rosetrees Trust.
The other participants report no disclosures.
CME expires three years after publication date or sooner if podcasts are deemed out of date by reviewers.
The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Credit™
The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Neurology holds copyright for all materials in this exam.
Any information regarding the identity of individuals taking the exam or their exam scores will be kept confidential.
Hardware and Software Requirements
A computer with a web browser such as Internet Explorer, Firefox, Safari, or Google Chrome is required.
For More Information
Executive Editor, Neurology®